{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:06:30Z","timestamp":1793239590716,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006162","name":"FACEPE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) patients under immunosuppression were excluded from the main trials with sodium\u2013glucose co-transporter 2 inhibitors. This trial aims to analyse the effect and safety of dapagliflozin in inactive LN patients with residual proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recruited adult LN patients (class III, IV(\u00b1V)] without activity, with proteinuria &amp;gt;500\u00a0mg\/24\u00a0h and an estimated glomerular filtration rate (eGFR) \u226520\u00a0ml\/min, on maintenance treatment with stable renin\u2013angiotensin\u2013aldosterone system inhibitors and mycophenolate mofetil \u22642\u00a0g\/day. They were randomized to receive dapagliflozin on top of standard-of-care (SoC) therapy or not. After 6\u00a0months the groups were crossed over. The primary endpoint is a reduction of proteinuria compared with baseline (6 and 12\u00a0months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6\u00a0months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. The mean age was 40.6\u00a0\u00b1\u00a012.3\u00a0years, 19 (90.5%) were female, none had diabetes and the mean body mass index was 26.1\u00a0\u00b1\u00a05.2. The final analysis showed a significant reduction in proteinuria of \u221236.1% in patients after 6\u00a0months of dapagliflozin as opposed to \u22123.5% for those in the SoC therapy group (P\u00a0=\u00a0.03). There were more reported hypotension symptoms in the dapagliflozin group [7 cases (33.3%)] but no drug withdrawal and no significant changes in blood pressure or weight in the follow-up between the groups. There was one case of urinary infection in each group, but in the same patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf257","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T13:00:51Z","timestamp":1764421251000},"page":"1253-1261","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3638","authenticated-orcid":false,"given":"Gisele","family":"Vajgel","sequence":"first","affiliation":[{"name":"EBSERH Federal University of Pernambuco Nephrology Department, Hospital das Cl\u00ednicas, , Recife ,","place":["Brazil"]},{"name":"Medical Sciences Center, Federal University of Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braziliano Miguel da Silva","family":"J\u00fanior","sequence":"additional","affiliation":[{"name":"Keizo Asami Institute, Federal University of Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R Silva Miranda","family":"Filho","sequence":"additional","affiliation":[{"name":"Medical Sciences Center, Federal University of Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-923X","authenticated-orcid":false,"given":"Camila Barbosa Lyra","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"EBSERH Federal University of Pernambuco Nephrology Department, Hospital das Cl\u00ednicas, , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Maria do Nascimento","family":"Costa","sequence":"additional","affiliation":[{"name":"EBSERH Federal University of Pernambuco Nephrology Department, Hospital das Cl\u00ednicas, , Recife ,","place":["Brazil"]},{"name":"Medical Sciences Center, Federal University of Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Albertina Dantas","family":"de Lima","sequence":"additional","affiliation":[{"name":"Keizo Asami Institute, Federal University of Pernambuco , Recife ,","place":["Brazil"]},{"name":"Federal University of Pernambuco Department of Oceanography, , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila Maria","family":"Valente","sequence":"additional","affiliation":[{"name":"EBSERH Federal University of Pernambuco Nephrology Department, Hospital das Cl\u00ednicas, , Recife ,","place":["Brazil"]},{"name":"Medical Sciences Center, Federal University of Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sandrin-Garcia","sequence":"additional","affiliation":[{"name":"Keizo Asami Institute, Federal University of Pernambuco , Recife ,","place":["Brazil"]},{"name":"Federal University of Pernambuco Department of Genetics, , Recife ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026062922483787300_bib1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026062922483787300_bib2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"1S","key":"2026062922483787300_bib4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ndt\/gfad230","article-title":"EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association-Immunonephrology Working Group (ERA-IWG) perspective","volume":"39","author":"Frangou","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922483787300_bib6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s42358-024-00386-8","article-title":"II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment","volume":"64","author":"dos Reis-Neto","year":"2024","journal-title":"Adv Rheumatol"},{"key":"2026062922483787300_bib7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","article-title":"Histologic versus clinical remission in proliferative lupus nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922483787300_bib8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/0961203313518625","article-title":"The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients","volume":"23","author":"Alvarado","year":"2014","journal-title":"Lupus"},{"key":"2026062922483787300_bib9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ekir.2020.04.005","article-title":"Low-grade proteinuria does not exclude significant Kidney injury in lupus nephritis","volume":"5","author":"De Rosa","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026062922483787300_bib11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ki.2010.525","article-title":"Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus","volume":"79","author":"Reich","year":"2011","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib12","doi-asserted-by":"publisher","first-page":"ii50","DOI":"10.1093\/ndt\/gfad069","article-title":"CKD therapy to improve outcomes of immune-mediated glomerular diseases","volume":"38","author":"Anders","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922483787300_bib13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.05040513","article-title":"Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis","volume":"9","author":"Parikh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026062922483787300_bib14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4S","key":"2026062922483787300_bib15","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026062922483787300_bib17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/nejmoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062922483787300_bib18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib19","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922483787300_bib20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026062922483787300_bib21","doi-asserted-by":"publisher","first-page":"e002686","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"2026062922483787300_bib22","doi-asserted-by":"publisher","first-page":"e2416578","DOI":"10.1001\/jamanetworkopen.2024.16578","article-title":"Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus","volume":"7","author":"Yen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026062922483787300_bib23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.43037","article-title":"Efficacy and safety of sodium\u2013glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with systemic lupus erythematosus and comorbid Type 2 diabetes: a population-based target trial emulation","volume":"77","author":"Ma","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026062922483787300_bib24","doi-asserted-by":"publisher","first-page":"152746","DOI":"10.1016\/j.semarthrit.2025.152746","article-title":"Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: a national cohort study","volume":"73","author":"Sagy","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026062922483787300_bib25","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026062922483787300_bib26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026062922483787300_bib27","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026062922483787300_bib28","doi-asserted-by":"publisher","first-page":"e000389","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2026062922483787300_bib29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026062922483787300_bib30","doi-asserted-by":"publisher","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2026062922483787300_bib31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026062922483787300_bib32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: redefining the treatment goals","volume":"107","author":"De Vriese","year":"2025","journal-title":"Kidney Int"},{"key":"2026062922483787300_bib33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1177\/0961203313505927","article-title":"Renoprotective strategies in lupus nephritis: beyond immunosuppression","volume":"22","author":"Griffin","year":"2013","journal-title":"Lupus"},{"key":"2026062922483787300_bib34","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"2026062922483787300_bib35","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1681\/ASN.2006040377","article-title":"How does proteinuria cause progressive renal damage?","volume":"17","author":"Abbate","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026062922483787300_bib36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026062922483787300_bib37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/art.43130","article-title":"Target trial emulations of sodium-glucose cotransporter 2 inhibitors in systemic lupus erythematosus","volume":"77","author":"Pope","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 9","key":"2026062922483787300_bib38","first-page":"abstract 1579","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of cardiac and renal outcomes in systemic lupus erythematosus","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf257\/65665097\/gfaf257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1253\/65665097\/gfaf257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/7\/1253\/65665097\/gfaf257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:48:44Z","timestamp":1782787724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/7\/1253\/8362054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf257","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,1]]}}}